•    

All fields are required.

Close Appointment form

Scientific Publications

Improving patient outcomes with innovative drug therapies.

Scientific Publications

The links on this page are not affiliated with Rockwell Medical, Inc. Links to sites outside of Rockwell Medical are provided as a resource to the viewer. Rockwell Medical accepts no responsibility for the content of linked sites.

Ferric pyrophosphate citrate (Triferic®) administration via the dialysate maintains hemoglobin and iron. Nephrol Dial Transplant(2015) 30: 2019 – 2026 doi: 10.1093/ndt/gfv277 Advance Access publication 13

Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century Drugs (2016). DOI 10.1007/s40265-016-0569-0; Published online 18 April 2016

Triferic® Human Intravenous (IV) Pharmacokinetic StudyThe Journal of Clinical Pharmacology (2016). DOI:10.1002/jcph.819

Ferric Pyrophosphate Citrate: A Novel Iron Replacement Agent in Patients Undergoing Hemodialysis Seminars in Nephrology | March 2016

Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients. Kidney International. (2015) 88, 1187–1194; doi:10.1038/ki.2015.203; published online 8 July 2015.